Product Details
Appearance:white crystalline powder
Reliable quality Ipriflavone 35212-22-7 global trade, in bulk supply
- Molecular Formula:C18H16O3
- Molecular Weight:280.323
- Appearance/Colour:white crystalline powder
- Vapor Pressure:8.47E-08mmHg at 25°C
- Melting Point:116-120 °C(lit.)
- Refractive Index:1.592
- Boiling Point:435.9 °C at 760 mmHg
- Flash Point:209.3 °C
- PSA：39.44000
- Density:1.184 g/cm3
- LogP:4.24720
35212-22-7 Usage
Ipriflavone is a semi-synthetic compound derived from soy and is used by humans as an alternative to hormone replacement, similar to phytohormones. Ipriflavone as an inflammasome-modulatory drug had potential effects on osteoimmune response. It also may partially contribute to the improvement of synovial inflammation and may be an option to support the treatment of RA.
Definition
ChEBI: A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women.
InChI:InChI=1/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3
35212-22-7 Relevant articles
Ipriflavone as a non-steroidal glucocorticoid receptor antagonist ameliorates diabetic cognitive impairment in mice
Ruifang Nie, Jian Lu, Rui Xu, Juanzhen Yang, Xingyi Shen, Xingnan Ouyang, Danyang Zhu, Yujie Huang, Tong Zhao, Xuejian Zhao, Yin Lu, Minyi Qian, Jiaying Wang, Xu Shen
, Aging Cell Volume21, Issue3 March 2022
Here, we determined that ipriflavone (IP) a clinical anti-osteoporosis drug functioned as a non-steroidal GR antagonist and efficiently ameliorated learning and memory dysfunction in both type 1 and 2 diabetic mice.
In vivo Ipriflavone Mutagenicity and Cytotoxicity after Repeated Treatment Doses
Jean Carlos Vencioneck Dutra , Paula Roberta Costalonga Pereira , Juliana Macedo Delarmelina , Luciano Belcavello and Maria do Carmo Pimentel Batitucci
Journal of Pharmacy and Pharmacology 10 (2022) 313-315
For the conditions tested, the treatment clinic dose (8.57 mg.kg-1 ) was the only one that did not induce mutagenic or cytotoxic damage. Our findings reinforce the safe use of ipriflavone and corroborate those found in the literature.
35212-22-7 Process route
-
- 13057-72-2
7-hydroxyisoflavone
-
- 75-26-3
isopropyl bromide
-
- 35212-22-7
Ipriflavone
| Conditions | Yield |
|---|---|
|
With potassium carbonate; In N,N-dimethyl-formamide; at 75 - 100 ℃; for 2.16667h;
|
93% |
|
With potassium carbonate; In N,N-dimethyl-formamide; at 80 ℃; for 4h;
|
42% |
|
With potassium carbonate; In DMF (N,N-dimethyl-formamide); at 80 ℃; for 4h;
|
42% |
|
With potassium carbonate; In N,N-dimethyl-formamide;
|
-
- 13057-72-2
7-hydroxyisoflavone
-
- 75-26-3
isopropyl bromide
-
- 78-92-2,15892-23-6
iso-butanol
-
- 35212-22-7
Ipriflavone
| Conditions | Yield |
|---|---|
|
With potassium carbonate; In N-methyl-acetamide; ethanol; water;
|
96.6% |
35212-22-7 Upstream products
-
75-30-9
2-iodo-propane
-
13057-72-2
7-hydroxyisoflavone
-
75-26-3
isopropyl bromide
-
3669-41-8
1-(2,4-dihydroxyphenyl)-2-phenylethanone
35212-22-7 Downstream products
-
163618-93-7
methyl 2-hydroxy-4-isopropyl benzoate
-
1179998-08-3
2-(2-hydroxy-4-isopropoxyphenyl)-3-phenyl-pyrimido[1,2-a]benzimidazole
-
1233690-14-6
3-hydroxy-5-phenyl-6-(2-hydroxy-4-isopropoxyphenyl)-1H-pyrazolo[3,4-b]pyridine
-
1232561-77-1
6-phenyl-7-(2-hydroxy-4-isopropoxyphenyl)-[1,2,4]triazolo[4,3-a]pyrimidine
Relevant Products
-
1,2,6,7-Tetrahydro-8H-indeno[5,4-b]furan-8-one 196597-78-1CAS：196597-78-1
-
Methenolone AcetateCAS：434-05-9
-
Coenzyme Q10CAS：303-98-0
